Charles River to expand Ireland manufacturing site to add Covid-19 vaccine capacity
Contract researcher Charles River Laboratories has taken advantage of the hot manufacturing market, extending its CDMO arm through a flurry of mergers and acquisitions. In a change of pace, it will add on to its already existing Ballina, Ireland location, expanding its testing capabilities in a $9.52 million deal that will add another 90 roles to the team in the next three years.
The deal will benefit AstraZeneca as Charles River will provide testing and deployment of the drugmaker’s Covid-19 vaccine Vaxzevria and flu vaccine Fluenz, Irish public broadcasting station RTE reports. The facility was established in 1974 and acquired by Charles River in 2002.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.